Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer.
PSMA PET
metastastases directed therapy
metastatic disease
oligometastatic
prostate cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
04
2022
accepted:
28
07
2022
entrez:
5
9
2022
pubmed:
6
9
2022
medline:
6
9
2022
Statut:
epublish
Résumé
Oligometastatic prostate cancer (OMPC) has been proposed as an intermediary state between localised disease and widespread metastases, with varying definitions including 1, 3, or ≤5 visceral or bone metastasis. Traditional definitions of OMPC are based on staging with conventional imaging, such as computerised tomography (CT) and whole-body bone scan (WBBS). Novel imaging modalities such as prostate-specific membrane antigen positron emission tomography (PSMA PET) have improved diagnostic utility in detecting early metastatic prostate cancer (PC) metastases compared with conventional imaging. Specifically, meta-analytical data suggest that PSMA PET is sensitive in detecting oligometastatic disease in patients with biochemical recurrence (BCR) post-radical treatment of PC. Recent trials have evaluated PSMA PET-guided metastases-directed therapy (MDT) in oligometastatic recurrent disease, typically with salvage surgery or radiotherapy (RT). To date, these preliminary studies demonstrate promising results, potentially delaying the need for systemic therapy. We aim to report a comprehensive, multidisciplinary review of PSMA-guided MDT in OMPC. In this review, we highlight the utility of PMSA PET in biochemically recurrent disease and impact of PSMA PET on the definition of oligometastatic disease and outline data pertaining to PSMA-guided MDT.
Identifiants
pubmed: 36059632
doi: 10.3389/fonc.2022.929444
pmc: PMC9433573
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
929444Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2022 Alberto, Yim, Papa, Siva, Ischia, Touijer, Eastham, Bolton and Perera.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Strahlenther Onkol. 2015 Apr;191(4):310-20
pubmed: 25326142
Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):546-555
pubmed: 31730876
BMC Cancer. 2020 May 12;20(1):406
pubmed: 32398040
Eur Urol Focus. 2020 Mar 15;6(2):231-234
pubmed: 31248850
BJU Int. 2021 Sep;128(3):331-342
pubmed: 33682320
Clin Cancer Res. 2019 Dec 15;25(24):7448-7454
pubmed: 31511295
Urology. 1998 Oct;52(4):637-40
pubmed: 9763084
Eur Urol. 2015 Sep;68(3):497-505
pubmed: 26119559
J Urol. 2007 Feb;177(2):540-5
pubmed: 17222629
Front Oncol. 2021 May 10;11:640467
pubmed: 34041020
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
Eur Urol. 2016 Jan;69(1):9-12
pubmed: 26189689
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
Asian J Androl. 2022 Jan-Feb;24(1):97-101
pubmed: 34213490
Eur Urol. 2015 May;67(5):852-63
pubmed: 25240974
Cancer Lett. 2006 May 18;236(2):229-38
pubmed: 16046056
J Nucl Med. 2021 May 14;:
pubmed: 33990403
J Clin Oncol. 2018 Apr 10;36(11):1080-1087
pubmed: 29384722
Eur Urol. 2020 Apr;77(4):403-417
pubmed: 30773328
Pulm Med. 2012;2012:541656
pubmed: 22991663
Eur Urol. 2021 Sep;80(3):374-382
pubmed: 33685838
N Engl J Med. 2009 Mar 26;360(13):1320-8
pubmed: 19297566
Urology. 2014 Mar;83(3):664-9
pubmed: 24411213
Clin Genitourin Cancer. 2021 Jun;19(3):230-236
pubmed: 32863189
Eur Urol. 2019 Jan;75(1):176-183
pubmed: 30301694
BJU Int. 2017 Nov;120(5):673-681
pubmed: 28548372
Radiat Oncol. 2014 Jun 12;9:135
pubmed: 24920079
J Urol. 2001 Apr;165(4):1146-51
pubmed: 11257657
Tumori. 2011 Jan-Feb;97(1):49-55
pubmed: 21528664
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Oncol. 1995 Jan;13(1):8-10
pubmed: 7799047
Cancers (Basel). 2019 May 23;11(5):
pubmed: 31126071
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Clin Genitourin Cancer. 2013 Mar;11(1):27-32
pubmed: 23010414
JAMA Oncol. 2020 May 1;6(5):650-659
pubmed: 32215577
Eur Urol. 2017 Sep;72(3):432-438
pubmed: 27600589
Clin Transl Oncol. 2021 Feb;23(2):364-371
pubmed: 32602076
Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):701-709
pubmed: 29280465
Front Oncol. 2013 Jan 22;2:215
pubmed: 23346551
Eur Urol Focus. 2021 Mar;7(2):250-253
pubmed: 33046413
J Urol. 2012 Dec;188(6):2190-7
pubmed: 23083862
Prostate. 2015 Dec;75(16):1934-40
pubmed: 26356236
Clin Exp Metastasis. 2020 Aug;37(4):551-560
pubmed: 32519046
Nat Rev Clin Oncol. 2011 Jun;8(6):378-82
pubmed: 21423255
Cancer Treat Rev. 2019 Feb;73:84-90
pubmed: 30684842
Lancet Oncol. 2019 May;20(5):686-700
pubmed: 30987939
Eur Urol. 2020 Nov;78(5):661-669
pubmed: 32624288
J Nucl Med. 2018 Feb;59(2):230-237
pubmed: 29123013
Eur Urol. 2019 Oct;76(4):493-504
pubmed: 30391078
Lancet. 2018 Dec 1;392(10162):2353-2366
pubmed: 30355464
Surg Oncol. 2018 Jun;27(2):138-145
pubmed: 29937163
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268
pubmed: 28497198
Minerva Urol Nefrol. 2018 Oct;70(5):462-478
pubmed: 29664244
Clin Cancer Res. 2021 Jul 1;27(13):3674-3682
pubmed: 33622706
Eur Urol. 2016 Dec;70(6):926-937
pubmed: 27363387
Eur Urol Oncol. 2021 Oct;4(5):714-730
pubmed: 33750684
Urol Oncol. 1995 Jan-Feb;1(1):18-28
pubmed: 21224086
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541
Int J Mol Sci. 2021 Nov 09;22(22):
pubmed: 34829977
Lancet Oncol. 2018 Oct;19(10):e534-e545
pubmed: 30303127
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
J Clin Oncol. 2006 Aug 20;24(24):3973-8
pubmed: 16921049
N Engl J Med. 1985 Jun 20;312(25):1604-8
pubmed: 4000199
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
Eur Urol. 2018 Oct;74(4):455-462
pubmed: 30227924
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):941-949
pubmed: 28138747
Eur Urol. 2019 Apr;75(4):659-666
pubmed: 29625755
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):486-95
pubmed: 23179945
Am Soc Clin Oncol Educ Book. 2019 Jan;39:309-320
pubmed: 31099652
BMC Cancer. 2020 Sep 14;20(1):884
pubmed: 32928177
Lancet Oncol. 2020 Jan;21(1):e18-e28
pubmed: 31908301